The study shows that the antibody called CIS43 protects against malaria better than any antibody that has been described before, said Marie Pancera, Biologist at the Fred Hutchinson Cancer Research Center in Washington.
‘A unique binding site was identified on the surface protein known as circumsporozoite protein (CSP) which could be used to design a vaccine that could tickle the immune system to produce CIS43 antibodies.’
Importantly, the study identified a unique binding site on the surface protein known as circumsporozoite protein (CSP) which could be used to design a vaccine that could tickle the immune system to produce such antibodies, Pancera added.
In the study, published in the journal Nature Medicine
, the human antibody was isolated from a protected subject who received an experimental vaccine containing whole, weakened malaria parasites.
The paired findings -- of both the antibody and the site it targets on the surface protein -- could open new pathways to malaria
After trials on humans, if the antibody is shown to be effective, it could be directly prescribed to the malaria patients, which may prevent the disease for up to six months. The currently available drugs needs to be taken daily, the researchers said.
According to the World Malaria Report 2016, there were 212 million cases of malaria globally in 2015, and 4,29,000 malaria deaths.
Malaria is caused by the Plasmodium parasite and spread to humans through the bite of an infected Anopheles mosquito.
Currently, only one experimental vaccine known as RTS,S has been found to protect about one-third of young children who received it.
While the RTS,S, which in phase three clinical trial, uses a fragment of CSP to elicit an immune response, it does not include the new site of vulnerability identified in the study.
This gives scientists the reason to believe that CIS43 would provide a broader protection from the disease.